[ET Net News Agency, 13 July 2021] Akeso, Inc. (09926) said CD47 monoclonal antibody
(research and development code: AK117), a second-generation novel drug for immuno-oncology
therapy independently developed by the company, has completed phase I dose escalation
trial in Australia.
AK117 resulted in no dose-limiting toxicity (DLT) and no anaemia of clinical
significance in subjects in all dose escalation cohorts (with 0.3 mg/kg to 45 mg/kg
administered once-weekly (QW)), and was well tolerated by subjects in all cohorts.
Low-dose priming was not required.
The company has obtained approval from the National Medical Products Administration
(NMPA) of the People's Republic of China to initiate phase Ib/II clinical trial of AK117
in combination with azacitidine for the treatment of acute myeloid leukaemia (AML). (RC)